- Home
- BROG vs ACRS Comparison
BROG vs ACRS Comparison
Compare BROG & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BROG
- ACRS
- Stock Information
- Founded
- BROG 2019
- ACRS 2012
- Country
- BROG United Arab Emirates
- ACRS United States
- Employees
- BROG N/A
- ACRS N/A
- Industry
- BROG Integrated oil Companies
- ACRS Biotechnology: Pharmaceutical Preparations
- Sector
- BROG Energy
- ACRS Health Care
- Exchange
- BROG Nasdaq
- ACRS Nasdaq
- Market Cap
- BROG 112.9M
- ACRS 132.0M
- IPO Year
- BROG N/A
- ACRS 2015
- Fundamental
- Price
- BROG $1.30
- ACRS $2.24
- Analyst Decision
- BROG
- ACRS Strong Buy
- Analyst Count
- BROG 0
- ACRS 5
- Target Price
- BROG N/A
- ACRS $11.00
- AVG Volume (30 Days)
- BROG 25.8K
- ACRS 647.4K
- Earning Date
- BROG 03-04-2025
- ACRS 02-25-2025
- Dividend Yield
- BROG N/A
- ACRS N/A
- EPS Growth
- BROG N/A
- ACRS N/A
- EPS
- BROG N/A
- ACRS N/A
- Revenue
- BROG $73,020,415.00
- ACRS $27,079,000.00
- Revenue This Year
- BROG N/A
- ACRS N/A
- Revenue Next Year
- BROG N/A
- ACRS N/A
- P/E Ratio
- BROG N/A
- ACRS N/A
- Revenue Growth
- BROG N/A
- ACRS 26.35
- 52 Week Low
- BROG $0.80
- ACRS $0.95
- 52 Week High
- BROG $6.66
- ACRS $5.17
- Technical
- Relative Strength Index (RSI)
- BROG 55.10
- ACRS 39.59
- Support Level
- BROG $1.02
- ACRS $2.11
- Resistance Level
- BROG $1.48
- ACRS $2.42
- Average True Range (ATR)
- BROG 0.09
- ACRS 0.15
- MACD
- BROG 0.04
- ACRS 0.00
- Stochastic Oscillator
- BROG 65.91
- ACRS 26.53
About BROG Brooge Energy Limited
Brooge Energy Ltd is an Oil Refinery & Storage Company in the United Arab Emirates. The company generates revenue from the leasing of storage capacity of tanks and other ancillary services.
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases. The contract research segment earns revenue from the provision of laboratory services. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777.